NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly Learn More about NanoViricides, Inc. by gaining access to the latest research report As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease. Since the first reports of monkeypox infection in the United States started popping up in May, cases have now been reported in all 50 states for a total of over 23,000 new infections . In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus. Here’s the company’s plan for bringing its monkeypox drug development platform to clinical trials sooner. NanoViricides’s Rapid Drug Development Program For Monkeypox Antiviral Having already begun drug development of NV-387-T, its monkeypox drug candidate, NanoViricides reports that it’s optimistic it can speed up the process to move the antiviral into human clinical trials quickly. Its reasons for that optimism are twofold. First, the active ingredient tecovirimat has already been approved by the Food and Drug Administration (FDA) as a smallpox treatment.